Patents Assigned to SINPHAR TIAN-LI PHARMACEUTICAL CO., LTD (HANGZHOU)
  • Uses of cistanche tubulosa extract and isoacteoside in protecting muscle
    Patent number: 9931367
    Abstract: Use of Cistanche tubulosa extract, isoacteoside and/or a pharmaceutical acceptable salt of isoacteoside in the manufacture of a medicament or a food product for protecting muscles, wherein the medicament is particularly used for protecting muscle cells against injury to regulate, treat and/or delay muscle loss, and especially for the muscle loss caused by aging, diseases, and/or cochexia. The food product is a health food, a nutritional supplement food, or a special nutrition food.
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: April 3, 2018
    Assignee: SINPHAR TIAN-LI PHARMACEUTICAL CO., LTD. (HANGZHOU)
    Inventors: Chao-Jih Wang, Ai-Ling Yeh
  • Pharmaceutical composition for treating or preventing angina or myocardial infarction induced by myocardial ischemia
    Patent number: 9446018
    Abstract: The present invention provides a pharmaceutical composition for the treatment and prophylaxis of angina and myocardial infarction, wherein a combination of a tea extract (catechins) and an antianginal drug are proved therapeutically potent in treating angina and mycocardial infarction induced from myocardial ischemia. The present invention also provides a use of a tea extract (catechins) in treating and preventing angina.
    Type: Grant
    Filed: July 10, 2009
    Date of Patent: September 20, 2016
    Assignee: SINPHAR TIAN-LI PHARMACEUTICAL CO., LTD. (HANGZHOU)
    Inventors: Muh-Hwan Su, Jing Jing Justine Tang, Hang-Ching Lin
  • Use of lanostane and extract in treating diabetes
    Patent number: 9084798
    Abstract: A pharmaceutical composition for treating diabetes is provided in this invention. The composition contains a lanostane compound as a potent component. A suitable source of the lanostane compound is a Poria extract from metabolite, sclerotium, or fermentation product of Poria cocos (Schw) Wolf. The Poria extract contains 1-60% of the lanostane compounds by weight of the extract, and is devoid of secolanostane.
    Type: Grant
    Filed: August 10, 2010
    Date of Patent: July 21, 2015
    Assignee: Sinphar Tian-Li Pharmaceutical Co., Ltd (Hangzhou)
    Inventors: Hang-Ching Lin, Yu-Chuan Huang, Tsu-Chung Chang, Wen-Liang Chang
  • METHOD FOR PREVENTING OR TREATING AMYLOID BETA PEPTIDE-ASSOCIATED DISEASES OR CONDITIONS, AND METHOD FOR INHIBITING FORMATION, ACCUMULATION OR AGGREGATION OF AMYLOID BETA PEPTIDES
    Publication number: 20120009131
    Abstract: Isoacteoside or a pharmaceutically acceptable salt thereof is used to prevent or treat amyloid beta peptide-associated diseases or conditions as an agent for inhibiting formation, accumulation or aggregation of amyloid beta peptides.
    Type: Application
    Filed: June 15, 2011
    Publication date: January 12, 2012
    Applicant: Sinphar Tian-Li Pharmaceutical Co., Ltd. (Hangzhou)
    Inventors: Hang-Ching LIN, Jing Jing Justine TANG, Muh-Hwan SU, Young-Ming HUANG
  • USE OF LANOSTANE AND PORIA EXTRACT IN TREATING DIABETES
    Publication number: 20110053899
    Abstract: A pharmaceutical composition for treating diabetes is provided in this invention. The composition contains a lanostane compound as a potent component. A suitable source of the lanostane compound is a Poria extract from metabolite, sclerotium, or fermentation product of Poria cocos (Schw) Wolf. The Poria extract contains 1-60% of the lanostane compounds by weight of the extract, and is devoid of secolanostane.
    Type: Application
    Filed: August 10, 2010
    Publication date: March 3, 2011
    Applicant: SINPHAR TIAN-LI PHARMACEUTICAL CO., LTD (HANGZHOU)
    Inventors: Hang-Ching Lin, Yu-Chuan Huang, Tsu-Chung Chang, Wen-Liang Chang
  • USE OF LANOSTANE AND PORIA EXTRACT IN TREATING CACHEXIA
    Publication number: 20100279992
    Abstract: A pharmaceutical composition for treating cachexia, and in particular for treating cancer cachexia. The composition contains a lanostane compound as a potent component. A suitable source of the lanostane compound is a Poria extract from metabolite, sclerotium, or fermentation product of Poria cocos (Schw) Wolf. The Poria extract contains 1-60% of the lanostane compounds by weight of the extract, and is devoid of secolanostane.
    Type: Application
    Filed: April 30, 2010
    Publication date: November 4, 2010
    Applicant: SINPHAR TIAN-LI PHARMACEUTICAL CO., LTD (HANGZHOU)
    Inventor: Hang-Ching Lin